Claas Wesseler - Dissemin

Papers authored by Claas Wesseler

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

2020 Wolfgang Brueckl, Achim Rittmeyer, Lens Kollmeier, Claas Wesseler

, Gunther Wiest, Martin Reck, Michael Thomas, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernahard Ulm, Fabian Reich, Joachim Ficker, Heinz-Eckart Laack

Efficacy of Docetaxel/Ramucirumab as Palliative Third-Line Therapy Immediately after Second-Line Immune-Checkpoint Inhibitor (ICI) Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC) UICC Stage IV

Upload

H. O. Ramdani, S. Shatz, M. Falk, L. C. Heukamp, M. Tiemann, C. Wesseler

, E. Schuuring, H. J. Groen, F. Griesinger

Evaluation of combined biomarker in response to immunotherapy (I/O) in patients with advanced non-small cell lung cancer (NSCLC)

Upload

2019 J. Roeper, M. Falk, S. Schatz, M. Tiemann, L. Heukamp, C. Wesseler

, G. H. Wiest, S. Sackmann, D. Ukena, F. Griesinger

Treatment patterns of EGFR mt plus NSCLC IV pts: Real-world data of the NOWEL network

Upload

J. Roeper, A. C. Lueers, M. Falk, S. Schatz, M. Tiemann, C. Wesseler

, G. H. Wiest, S. Sackmann, D. Ukena, L. Heukamp, F. Griesinger

Risk of not receiving second-line therapy is high in EGFR mt plus patients: Real-world data of certified lung cancer centers on treatment sequence in EGFR mt plus patients

Upload

J. Roeper, M. Falk, S. Schatz, M. Tiemann, C. Wesseler

, G. H. Wiest, D. Ukena, S. Sackmann, F. Griesinger

Treatment patterns of EGFR mt plus NSCLC IV patients: real world data of the NOWEL network

Upload

This paper was not found in any repository, but could be made available legally by the author.

2018 M. Thomas, S. Ponce-Aix, A. Navarro, J. Riera-Knorrenschild, M. Schmidt, E. Wiegert, K. Kapp, B. Wittig, C. Mauri, M. Dómine Gómez, J. Kollmeier, P. Sadjadian, K.-P. Fröhling, R. M. Huber, M. Wolf and 22 other authors

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

Upload

J. Roeper, M. Falk, S. Schatz, M. Tiemann, S. Sackmann, D. Ukena, C. Wesseler

, G. Wiest, L. Heukamp, F. Griesinger

P1.01-82 Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts

Upload

This paper is made freely available by the publisher.

Jonathan Wade Goldman, Julien Mazieres, Fabrice Barlesi, Marianna Koczywas, Konstantin H. Dragnev, Tuncay Göksel, Alexis B. Cortot, Nicolas Girard, Claas Wesseler

, Helge Bischoff, Ernest Nadal, Keunchil Park, Shun Lu, Alvaro Taus, Manuel Cobo and 5 other authors

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

Download from doi.org

Julia Roeper, Markus Falk, Markus Tiemann, Claas Wesseler

, Gunther Wiest, Sandra Sackmann, Dieter Ukena, Lukas Heukamp, Frank Griesinger

Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts.

Download from doi.org

J. Roeper, M. Netchaeva, A. Lueers, M. Falk, M. Tiemann, C. Wesseler

, G. Wiest, S. Sackmann, D. Ukena, F. Griesinger

163P The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network

Upload

J. Roeper, M. Falk, S. Schatz, M. Tiemann, C. Wesseler

, G. Wiest, S. Sackmann, D. Ukena, L. C. Heukamp, F. Griesinger

Risk of not receiving second-line therapy is high in EGFR mt plus pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt plus pts

Upload

J. Roeper, M. Falk, S. Schatz, M. Tiemann, C. Wesseler

, G. Wiest, S. Sackmann, D. Ukena, L. Heukamp, F. Griesinger

Risk of not receiving 2nd line therapy is high in EGFR mt plus patients: Real world data of certified lung cancer centers on treatment sequence in EGFR mt plus patients

Upload

M. Thomas, C. Grohe, W. Eberhardt, J. Rawluk, M. Reck, E. Laack, C. Wesseler

, A. Rittmeyer, J. Alt, N. Reinmuth, F. Griesinger, J. Kern

POSEIDON: A phase 3 study of first-line Durvalumab +/- Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC

Upload

2017 C. Wesseler

Neues zur molekular gezielten Therapie

Upload

J. Roeper, M. Netchaeva, A. Lueers, C. Hallas, M. Falk, M. Tiemann, N. Neemann, L. Heukamp, C. Wesseler

, G. Wiest, S. Sackmann, D. Ukena, F. Griesinger

P3.01-038 Impact on OS and PFS of 2nd and 3rd Generation TKI in EGFR Mt+ and ALK+ Patients: Results of the NOWEL Network

Upload

Julia Roeper, Maria Netchaeva, Anne Christina Lueers, Ursula Stropiep, Cora Hallas, Markus Tiemann, Nicole Neemann, Lukas C. Heukamp, Markus Falk, Gunther Wiest, Claas Wesseler

, Dieter Ukena, Sandra Sackmann, Frank Griesinger

Impact on OS of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients: Results of the NOWEL network.

Download from doi.org

Julia Roeper, Maria Netchaeva, Anne Lueers, Ursula Stropiep, Cora Hallas, Markus Tiemann, Nicole Neemann, Lukas Heukamp, Markus Falk, Gunther Wiest, Claas Wesseler

, Dieter Ukena, Sandra Sackmann, Frank Griesinger

P2.03b-022 Outcome in Molecularly Defined NSCLC within the NOWEL Network: The Influence of Sequential 2nd and 3rd Generation TKI in EGFR mt+ and ALK+ pts

Upload

J. Roeper, M. Netchaeva, M. Netcheva, A. Lueers, C. Hallas, M. Falk, M. Tiemann, N. Neemann, L. Heukamp, G.-H. Wiest, C. Wesseler

, D. Ukena, S. Sackmann, F. Griesinger

Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt plus and ALK plus patients: results of the NOWEL network

Upload

J. Roeper, A. Lueers, M. Netchaeva, M. Falk, C. Hallas, M. Tiemann, N. Neemann, L. Heukamp, C. Wesseler

, G. H. Wiest, D. Ukena, S. Sackmann, F. Griesinger

Impact on OS and PFS of 2nd and 3rd generation TKI in EGFR mt1 and ALK1 pts: Results of the NOWEL network

Upload

Missing publications? Search for publications with a matching author name.

Researcher

Statistics

Refine

Papers authored by Claas Wesseler